Valuation: BICO Group AB

Market Cap 1.54B 155M 136M 128M 117M 219M 14.83B 220M 594M 7.57B 580M 568M 24.32B P/E 2026 *
-6.77x
P/E 2027 * -12.2x
Enterprise Value 1.47B 148M 130M 123M 111M 209M 14.17B 210M 568M 7.23B 554M 542M 23.23B EV / Sales 2026 *
0.91x
EV / Sales 2027 * 0.81x
Free-Float
69.88%
Yield 2026 *
-
Yield 2027 * -
1 week-0.72%
Current month-1.22%
1 month+2.00%
3 months+32.97%
6 months+26.21%
Current year+0.31%
1 week 1.92
Extreme 1.92
2.02
1 month 1.8
Extreme 1.804
2.05
3 years 1.17
Extreme 1.172
6.4
5 years 1.17
Extreme 1.172
52.5
Manager TitleAgeSince
Chief Executive Officer 51 2026-08-31
Director of Finance/CFO 56 2026-02-28
Chief Operating Officer - 2026-01-06
Director TitleAgeSince
Director/Board Member 70 2019-12-17
Director/Board Member 37 2015-02-28
Director/Board Member - 2026-05-06
Change 5-day change 1-year change 3-year change Capi.($)
-2.12%+0.41%+2.65%-23.48% 158M
+0.53%+4.17%+46.17%+36.19% 250B
+1.27%+7.33%+22.99%-8.13% 158B
+2.37%+5.46%-5.97%+42.33% 143B
+0.43%+1.78%-55.07%-15.34% 63.65B
+0.63%-1.62%+13.88%+23.85% 49.74B
+1.40%+11.98%+42.00%+58.56% 48.71B
+2.33%+2.38%-14.54%-18.18% 47.94B
+2.17%+5.05%+51.84%+62.64% 42.59B
+0.70%+13.47%+196.54%+103.98% 40.77B
Average +1.14%+4.19%+30.05%+26.24% 93.77B
Weighted average by Cap. +0.94%+4.03%+27.31%+27.13%

Financials

2026 *2027 *
Net sales 1.62B 163M 143M 135M 123M 231M 15.64B 232M 626M 7.98B 612M 598M 25.64B 1.69B 169M 149M 141M 128M 240M 16.25B 241M 651M 8.29B 635M 622M 26.64B
Net income -227M -22.8M -20.05M -18.96M -17.2M -32.29M -2.19B -32.48M -87.67M -1.12B -85.59M -83.73M -3.59B -126M -12.65M -11.13M -10.52M -9.54M -17.93M -1.21B -18.03M -48.66M -620M -47.51M -46.48M -1.99B
Net Debt -69M -6.93M -6.09M -5.76M -5.23M -9.82M -665M -9.87M -26.65M -339M -26.02M -25.45M -1.09B -166M -16.67M -14.66M -13.86M -12.58M -23.62M -1.6B -23.75M -64.11M -817M -62.59M -61.23M -2.62B
Logo BICO Group AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
-
Date Price Change
26-09-28 €1.936 -2.12%
26-09-25 €1.978 -0.70%
26-09-24 €1.992 +0.40%
26-09-23 €1.984 +0.92%
26-09-22 €1.966 +0.82%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
21.80SEK
Average target price
29.00SEK
Spread / Average Target
+33.03%

Quarterly revenue - Rate of surprise